Alternative Data for Biomarin Pharmaceutical
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 123 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 96,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 6 | Sign up | Sign up | Sign up |
| Facebook Followers | 7,315 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,339 | Sign up | Sign up | Sign up |
| X Mentions | 34 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 2,050 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 23 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,169 | Sign up | Sign up | Sign up |
About Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Price | $56.30 |
| Target Price | Sign up |
| Volume | 1,561,195 |
| Market Cap | $11B |
| Year Range | $51.46 - $64.08 |
| Dividend Yield | 0% |
| PE Ratio | 31.78 |
| Analyst Rating | 85% buy |
| Industry | Biotechnology |
In the news
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study DiscontinuationsMarch 30 - Yahoo Entertainment |
|
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGOMarch 18 - Yahoo Entertainment |
|
Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here’s WhyFebruary 27 - Yahoo Entertainment |
|
 |
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From MarketFebruary 24 - Yahoo |
|
BioMarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...February 23 - Yahoo |
|
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key MetricsFebruary 23 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | -2.35B | -442M | -1.9B | -369M | -577M | 0.120 |
| Q2 '25 | 825M | 150M | 675M | 241M | 319M | 1.440 |
| Q1 '25 | 745M | 152M | 594M | 186M | 263M | 1.130 |
| Q4 '24 | 747M | 136M | 611M | 125M | 195M | 0.920 |
| Q3 '24 | 746M | 188M | 557M | 106M | 156M | 0.550 |
Insider Transactions View All
| Guyer Charles Greg filed to sell 79,953 shares at $60.5. March 12 '26 |
| Friberg Gregory R filed to sell 37,578 shares at $60.4. February 26 '26 |
| Davis George Eric filed to sell 72,453 shares at $61.4. February 26 '26 |
| Burkhart Erin filed to sell 14,173 shares at $59.3. May 20 '25 |
| Hubbard Cristin filed to sell 32,700 shares at $64.9. May 6 '25 |
Similar companies
Read more about Biomarin Pharmaceutical (BMRN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Biomarin Pharmaceutical
The Market Cap of Biomarin Pharmaceutical is $11B.
As of today, Biomarin Pharmaceutical's PE (Price to Earnings) ratio is 31.78.
Currently, the price of one share of Biomarin Pharmaceutical stock is $56.30.
The BMRN stock price chart above provides a comprehensive visual representation of Biomarin Pharmaceutical's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biomarin Pharmaceutical shares. Our platform offers an up-to-date BMRN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Biomarin Pharmaceutical (BMRN) does not offer dividends to its shareholders. Investors interested in Biomarin Pharmaceutical should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Biomarin Pharmaceutical are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
